

115TH CONGRESS 1ST SESSION

H. RES. 420

Expressing support for the designation of the week of July 9 through July 15, 2017, as "Sarcoma Awareness Week" and July 15, 2017, as "Leiomyosarcoma Awareness Day".

IN THE HOUSE OF REPRESENTATIVES

June 28, 2017

Mr. LEVIN submitted the following resolution; which was referred to the Committee on Energy and Commerce

RESOLUTION

Expressing support for the designation of the week of July 9 through July 15, 2017, as "Sarcoma Awareness Week" and July 15, 2017, as "Leiomyosarcoma Awareness Day".

- Whereas a soft tissue sarcoma is a rare type of cancer, accounting for approximately 1 percent of all newly diagnosed cancers, that arises in the connective tissue of the body;
- Whereas the National Institutes of Health designates sarcoma as a rare form of cancer, with sarcoma containing approximately 70 different subtypes;
- Whereas sarcomas are largely resistant to current chemotherapy agents, immunotherapy agents, and radiation

- therapies, posing a formidable challenge for researchers and specialists;
- Whereas sarcoma subtypes have largely not received benefit from immunotherapies due to the complexity of the DNA, genomes, and mutations associated with the many variations in the sarcoma subtype landscape;
- Whereas leiomyosarcoma (referred to in this preamble as "LMS") is a malignant, aggressive subtype of soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal, or soft tissue origin, and can metastasize to the bone, spine, brain, and liver;
- Whereas the National Institutes of Health classifies LMS as a rare disease, accounting for approximately 15 percent of all sarcomas, and LMS itself encompasses at least 4 different LMS subtypes;
- Whereas LMS primarily affects adults without regard to gender;
- Whereas research and clinical trials for LMS remain complicated, and the prospects for long-term survival remain poor;
- Whereas multidisciplinary care coordination teams, because of their expertise and experience, are critical to the health of sarcoma and LMS patients;
- Whereas sarcoma and LMS research will allow medical professionals to improve the quality of care for affected patients, lead to better clinical outcomes, and promote longer survival for patients; and
- Whereas increased education and awareness about sarcoma and LMS will contribute to the well-being of the communities of the United States: Now, therefore, be it

| 1 | Resolved, That the House of Representatives— |
|----|--|
| 2 | (1) supports the designation of "Sarcoma |
| 3 | Awareness Week"; |
| 4 | (2) supports the designation of "Leiomyosarco- |
| 5 | ma Awareness Day''; |
| 6 | (3) recognizes the challenges faced by sarcoma |
| 7 | and leiomyosarcoma patients; and |
| 8 | (4) commends the dedication of organizations, |
| 9 | volunteers, researchers, and caregivers across the |
| 10 | country working to improve the quality of life of sar- |
| 11 | coma and leiomyosarcoma patients and their fami- |
| 12 | lies. |

 \bigcirc